LINE

Text:AAAPrint
Society

Drugs from overseas to get on fast track

1
2017-07-14 09:38:32China Daily Feng Shuang ECNS App Download

Regulators, pharmaceutical companies, researchers will adopt global standards

China will continue to intensify international exchanges and cooperation in drug supervision to promote the domestic application of new medicines developed overseas to meet demand, China's top drug regulator said on Thursday.

The drug authorities will also encourage the domestic pharmaceutical industry to improve its capacity and competitiveness to promote the international visibility of Chinese medical and pharmaceutical products, Wu Zhen, vice-minister of the China Food and Drug Administration, said at the opening ceremony of the BRICS Meeting on Drug Regulatory Collaboration in Zhengzhou, Henan province.

On June 19, the administration announced it joined the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, which focuses on guidelines for worldwide pharmaceutical development.

"Joining the council means the Chinese drug regulatory authorities, pharmaceutical industry and research and development institutes will gradually adopt internationally accepted standards and guidelines, actively participate in the formulation of international rules and promote quicker domestic application of new drugs developed in other countries," Wu said.

China is the second-largest market for pharmaceutical products in the world. Annual revenues of the pharmaceutical industry in China exceed 2.5 trillion yuan ($368.6 billion), and annual exports of pharmaceutical products exceed 13.5 billion yuan, Wu said.

"China has great pharmaceutical production capacity, so it can provide support to the health of the people in BRICS nations and other countries," he said.

BRICS comprises Brazil, Russia, India, China and South Africa.

The administration has adopted a series of reform measures on the review and approval of new drugs to accelerate approvals and meet the needs of domestic patients in recent years, Wu said.

The authorities will encourage medical institutions to give priority to new drugs that have proved effective and are reasonably priced, and support the inclusion of such new drugs in the list of drugs whose cost can be reimbursed by basic medical insurance programs, according to a draft regulation released by the administration in May.

Certain types of drugs and medical equipment already in use in other countries, such as those for curing rare diseases, can also gain priority approval for sale in the domestic market, the draft said.

As of the end of June, the administration had established routine work relations with drug regulatory authorities in 66 countries, and signed 42 agreements for bilateral cooperation with 28 countries and regions, said Yuan Lin, chief of the administration's international cooperation department.

  

Related news

MorePhoto

Most popular in 24h

MoreTop news

MoreVideo

News
Politics
Business
Society
Culture
Military
Sci-tech
Entertainment
Sports
Odd
Features
Biz
Economy
Travel
Travel News
Travel Types
Events
Food
Hotel
Bar & Club
Architecture
Gallery
Photo
CNS Photo
Video
Video
Learning Chinese
Learn About China
Social Chinese
Business Chinese
Buzz Words
Bilingual
Resources
ECNS Wire
Special Coverage
Infographics
Voices
LINE
Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2018 Chinanews.com. All rights reserved.
Reproduction in whole or in part without permission is prohibited.